Ranitidine, metformin, and topiramate: Managing weight gain in a clozapine-treated patient with schizoaffective disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 16, Issue 3, 2014, Pages

  Greg Deardorff, O ^a   Syed, Ahsan ^a   Ames, Chelsea J ^a   Yaeger, Jaclyn S ^a  

^a Fulton State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904264937     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13l01598     Document Type: Letter

References (17)

1. McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610. PubMed doi:10.1176/appi.ajp.163.4.600 Show Abstract
2. Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia? a decision-analytic model. J Ment Health Policy Econ. 2004;7(2):77-85. PubMed Show Abstract
3. Bitter I, Dossenbach MRK, Brook S, et al; Olanzapine HGCK Study Group. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):173-180. PubMed doi:10.1016/j.pnpbp.2003.09.033 Show Abstract
4. de Leon J, Diaz FJ, Josiassen RC, et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007;27(1):22-27. PubMed doi:10.1097/JCP.0b013e31802e513a Show Abstract
5. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002;70(1):19-26. PubMed doi:10.1016/S0165-0327(01)00456-6 Show Abstract
6. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women: risk within the 'normal' weight range. JAMA. 1995;273(6):461-465. PubMed doi:10.1001/jama.1995.03520300035033 Show Abstract
7. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry. 2005;39(6):479-486. PubMed Show Abstract
8. Sharpe JK, Stedman TJ, Byrne NM, et al. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry. 2006;40(9):810-814. PubMed doi:10.1080/j.1440-1614.2006.01888.x Show Abstract
9. López-Mato A, Rovner J, Illa G, et al. Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration [in Spanish]. Vertex. 2003;14(52):85-96. PubMed Show Abstract
10. Cavazzoni P, Tanaka Y, Roychowdhury SM, et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(2):81-85. PubMed doi:10.1016/S0924-977X(02)00127-X Show Abstract
11. Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol. 2004;14(4):332-336. PubMed doi:10.1016/j.euroneuro.2003.10.004 Show Abstract
12. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. PubMed doi:10.1056/NEJMoa012512 Show Abstract
13. Jarskog LF, Hamer RM, Catellier DJ, et al; METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032-1040. PubMed doi:10.1176/appi.ajp.2013.12010127 Show Abstract
14. Hahn MK, Remington G, Bois D, et al. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol. 2010;30(6):706-710. PubMed doi:10.1097/JCP.0b013e3181fab67d Show Abstract
15. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-814. PubMed doi:10.1001/jama.2014.732 Show Abstract
16. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. PubMed doi:10.1186/1471-2458-9-88 Show Abstract
17. Hasnain M, Vieweg WV. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013;125(5):117-129. PubMed doi:10.3810/pgm.2013.09.2706 Show Abstract